Skip to main content

Susan Halabi CV

James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
Duke Box 2717, Durham, NC 27710
2424 Erwin Road 11th Floor, 11088 Hock Plaza, Durham, NC 27705
CV

Overview


Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.

Current Appointments & Affiliations


James B. Duke Distinguished Professor of Biostatistics & Bioinformatics · 2023 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics · 2012 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Chief, Division of Biostatistics · 2019 - Present Biostatistics & Bioinformatics, Basic Science Departments
Member of the Duke Cancer Institute · 1996 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published February 12, 2025
New Blood Test for Advanced Prostate Cancer Patients
Published May 4, 2023
Duke Awards 44 Distinguished Professorships
Published June 4, 2018
Survival Benefit for African-Americans with Advanced Prostate Cancer

View All News

Recent Publications


Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance).

Journal Article Eur Urol Open Sci · May 2025 BACKGROUND AND OBJECTIVE: Cisplatin-based chemotherapy has been a cornerstone of therapy for advanced/metastatic urothelial cancer (mUC). However, no genomic characteristics have been validated as prognostic biomarkers for this therapy. We sought to identi ... Full text Link to item Cite

Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Journal Article ESMO Open · April 10, 2025 BACKGROUND: TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and targetable genomic alterations. Results of four patients with various tumors with NRG1 fusions tre ... Full text Link to item Cite

Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection.

Journal Article Lancet Reg Health Am · April 2025 BACKGROUND: Whether COVID-19 vaccination is associated with risks for cardiovascular complications after SARS-CoV-2 infection in patients with cancer is unknown. The objective of this study was to investigate the associations between the two. METHODS: This ... Full text Link to item Cite
View All Publications

Recent Grants


Research Triangle Center of Excellence in Regulatory Science and Innovation

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028

DoD: PCRP Clinical Consortium: Duke University Clinical Research Site

ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026

Understanding heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era

ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2026

View All Grants

Education, Training & Certifications


University of Texas Health Sciences Center, Houston · 1994 Ph.D.